Key result
Symptomatic depression linked to ~$4,000 higher annual healthcare costs in obese CVD patients.
Why the study?
There is a lack of information on the cost of depression associated with metabolic syndrome and cardiovascular diseases.
Do depression and obesity synergistically increase healthcare expenditures in patients with cardiovascular disease?
Observational (n=96,697)
Do depression and obesity synergistically increase healthcare expenditures in patients with cardiovascular disease?
Absolute Event Rate: 6246% vs 2271%
p-value: p=<0.001
Symptomatic depression and obesity are associated with significantly increased healthcare expenditures among patients with cardiovascular disease.
Depression screening may warrant consideration in obese CVD patients; leaves open whether treating depression reduces expenditures.
BACKGROUND: There is a lack of information on the cost of depression associated with metabolic syndrome and cardiovascular diseases in the literature. METHODS: We evaluated the synergistic effects of depression and obesity on total expenditures for cardiovascular conditions using data from the Medical Expenditure Panel Survey (MEPS) database. We analyzed MEPS data from 1996 to 2017 comprising adult cardiovascular subjects. We categorized individuals following a combination of International Classification of Diseases ICD-9-CM and ICD-10 codes, and depression symptoms as evaluated using the Patient Health Questionnaire-2 (PHQ-2) depression screening tool. Our sample comprised cardiovascular patients aged 18 years and older, with a body mass index (BMI) between 18.5 and 60. Our study comprised unweighted sample of 96,697 (weighted sample of 938,835,031) adults, a US-nationwide representative sample of cardiovascular disease patients. The four response categories were: no depression; unrecognized depression; asymptomatic depression; and symptomatic depression. Our evaluated outcomes were total annual healthcare expenditures, including dental, emergency room, hospital outpatient, hospital inpatient, office-based, prescription, and home health care expenses. RESULTS: Asymptomatic and symptomatic depression was more frequent among obese individuals than in individuals with a normal BMI (p < 0.001). Total expenditure was highest among symptomatic depression individuals (17,536) and obese (9871) with cardiovascular disease. All the expenditure outcomes were significantly higher among symptomatic depression individuals than those without depression (p < 0.001), except for dental costs. All healthcare expenditures associated with obesity were higher compared to individuals with normal BMI with p < 0.001, except for emergency and home healthcare costs. Most importantly, among obese individuals, all healthcare expenditures were significantly higher (p < 0.001) in those with symptomatic depression than those without depression, except for dental costs, where the difference was not significant (0.899). Therefore, obesity and depression entail increased expenses in patients with cardiovascular disease. CONCLUSIONS: We found incremental expenditures among unrecognized, asymptomatic, and symptomatic depressed individuals with obesity compared to non-depressed, non-obese subjects. However, these are preliminary results that should be further validated using different methodologies.
No takes yet. Share an insight, caveat, or question.
Tápias et al. (2021) conducted an observational in Cardiovascular disease with depression and obesity (n=96,697). Symptomatic depression vs. No depression was evaluated on Total annual healthcare expenditures among obese cardiovascular patients (predicted median in USD) (95% CI 5716-6825, p=<0.001). Among obese patients with cardiovascular disease, symptomatic depression was associated with significantly higher predicted median total annual healthcare expenditures compared to those without depression ($6,246 vs $2,271).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: